[go: up one dir, main page]

BRPI0409588A - composto, composição farmacêutica, métodos para ligar seletivamente ao receptor beta de estrogênio em um paciente, para tratar um paciente acometido de uma condição de enfermidade mediada com um receptor beta de estrogênio, para tratar cáncer de próstata e hiperplasia prostática benigna em um paciente, e, uso de um composto - Google Patents

composto, composição farmacêutica, métodos para ligar seletivamente ao receptor beta de estrogênio em um paciente, para tratar um paciente acometido de uma condição de enfermidade mediada com um receptor beta de estrogênio, para tratar cáncer de próstata e hiperplasia prostática benigna em um paciente, e, uso de um composto

Info

Publication number
BRPI0409588A
BRPI0409588A BRPI0409588-0A BRPI0409588A BRPI0409588A BR PI0409588 A BRPI0409588 A BR PI0409588A BR PI0409588 A BRPI0409588 A BR PI0409588A BR PI0409588 A BRPI0409588 A BR PI0409588A
Authority
BR
Brazil
Prior art keywords
patient
estrogen receptor
compound
beta
treating
Prior art date
Application number
BRPI0409588-0A
Other languages
English (en)
Inventor
Gregory Lee Durst
Bryan Hurst Norman
Lance Allen Pfeifer
Timothy Ivo Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0409588A publication Critical patent/BRPI0409588A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS PARA LIGAR SELETIVAMENTE AO RECEPTOR BETA DE ESTROGêNIO EM UM PACIENTE, PARA TRATAR UM PACIENTE ACOMETIDO DE UMA CONDIçãO DE ENFERMIDADE MEDIADA COM UM RECEPTOR BETA DE ESTROGêNIO, PARA TRATAR CáNCER DE PRóSTATA E HIPERPLASIA PROSTáTICA BENIGNA EM UM PACIENTE, E USO DE UM COMPOSTO". Esta invenção refere-se a heterociclos inéditos que são antagonistas do receptor 1 de hormónio concentrador de melanina (MCHR1), também referidos como 11CBy, a composições farmacêuticas contendo os mesmos, a processos para sua preparação, e a seu uso na medicina. Compostos da invenção têm a fórmula: (I)
BRPI0409588-0A 2003-04-21 2004-04-08 composto, composição farmacêutica, métodos para ligar seletivamente ao receptor beta de estrogênio em um paciente, para tratar um paciente acometido de uma condição de enfermidade mediada com um receptor beta de estrogênio, para tratar cáncer de próstata e hiperplasia prostática benigna em um paciente, e, uso de um composto BRPI0409588A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46440403P 2003-04-21 2003-04-21
PCT/US2004/009272 WO2004094400A2 (en) 2003-04-21 2004-04-08 Substituted benzopyrans as selective estrogen receptor-beta agonists

Publications (1)

Publication Number Publication Date
BRPI0409588A true BRPI0409588A (pt) 2006-04-18

Family

ID=33310882

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409588-0A BRPI0409588A (pt) 2003-04-21 2004-04-08 composto, composição farmacêutica, métodos para ligar seletivamente ao receptor beta de estrogênio em um paciente, para tratar um paciente acometido de uma condição de enfermidade mediada com um receptor beta de estrogênio, para tratar cáncer de próstata e hiperplasia prostática benigna em um paciente, e, uso de um composto

Country Status (17)

Country Link
US (3) US7442812B2 (pt)
EP (1) EP1626974B1 (pt)
JP (1) JP4481300B2 (pt)
CN (1) CN100374444C (pt)
AT (1) ATE406373T1 (pt)
AU (1) AU2004232798B2 (pt)
BR (1) BRPI0409588A (pt)
CA (1) CA2518819A1 (pt)
CY (1) CY1110443T1 (pt)
DE (1) DE602004016150D1 (pt)
DK (1) DK1626974T3 (pt)
ES (1) ES2311838T3 (pt)
MX (1) MXPA05011243A (pt)
PL (1) PL1626974T3 (pt)
PT (1) PT1626974E (pt)
SI (1) SI1626974T1 (pt)
WO (1) WO2004094400A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023085A (zh) * 2004-07-19 2007-08-22 詹森药业有限公司 用作雌激素受体调节剂的螺－苯并[c]色烯衍生物
CN101052641A (zh) 2004-09-07 2007-10-10 惠氏公司 6H－[1]苯并吡喃并[4,3－b]喹啉及其作为雌激素药物的用途
JP2008516949A (ja) 2004-10-18 2008-05-22 イーライ リリー アンド カンパニー 選択的エストロゲン受容体βアゴニストとしての置換ベンゾピラン
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
JP2006232727A (ja) * 2005-02-24 2006-09-07 Chisso Corp クマリン誘導体、この化合物を含有する液晶組成物およびこの液晶組成物を含有する液晶表示素子
KR101763674B1 (ko) 2007-01-22 2017-08-01 지티엑스, 인코포레이티드 핵 수용체에 결합하는 물질
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2011014516A1 (en) 2009-07-28 2011-02-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Estrogen antagonists as treatments for sclerosing disorders
CN109134493A (zh) * 2018-09-19 2019-01-04 浙江师范大学 一种具有抗菌活性的2-氧代色烯并噻吩衍生物及其合成方法和应用
CN109400564B (zh) * 2018-09-25 2021-03-12 信阳师范学院 一种含三氟甲基的苯并二氢吡喃-4-酮类化合物及其制备方法
CN110128393B (zh) * 2019-06-21 2022-09-30 华侨大学 一种取代异香豆素衍生物的制备方法
CN112898263B (zh) * 2021-01-28 2022-03-08 江西中医药大学 一种从佛手中分离的香豆素骈木脂素化合物及其保肝用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2135249T5 (es) 1995-09-08 2009-09-10 Karo Bio Ab Receptor de estrogenos.
WO1999002512A1 (en) 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
EP1163225A1 (en) * 1999-03-17 2001-12-19 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) * 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
IL145839A0 (en) * 1999-04-16 2002-07-25 Astrazeneca Ab ESTROGEN RECEPTOR-β LIGANDS
CN1281598C (zh) 1999-12-30 2006-10-25 信号药品公司 调节雌激素受体的化合物和方法
EP1282615B1 (en) * 2000-03-01 2011-10-19 N.V. Organon Chroman derivatives as estrogenic compounds
WO2001072713A1 (en) 2000-03-27 2001-10-04 Akzo Nobel N.V. Non-steroidal, tetracyclic compounds for estrogen-related treatments
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
JP2005501851A (ja) 2001-08-13 2005-01-20 ハーグリーブス リレイ，マイケル 毒素を除去するための組成物
CA2467013C (en) * 2001-11-19 2010-08-10 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists
WO2004094401A1 (en) 2003-04-21 2004-11-04 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
JP2008516949A (ja) 2004-10-18 2008-05-22 イーライ リリー アンド カンパニー 選択的エストロゲン受容体βアゴニストとしての置換ベンゾピラン
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists

Also Published As

Publication number Publication date
US20090298925A1 (en) 2009-12-03
PT1626974E (pt) 2008-11-14
CA2518819A1 (en) 2004-11-04
CN100374444C (zh) 2008-03-12
DK1626974T3 (da) 2008-11-17
ATE406373T1 (de) 2008-09-15
EP1626974B1 (en) 2008-08-27
WO2004094400A3 (en) 2005-02-24
CN1777614A (zh) 2006-05-24
PL1626974T3 (pl) 2009-01-30
AU2004232798B2 (en) 2010-04-22
ES2311838T3 (es) 2009-02-16
JP2006524240A (ja) 2006-10-26
JP4481300B2 (ja) 2010-06-16
WO2004094400A2 (en) 2004-11-04
SI1626974T1 (sl) 2009-02-28
EP1626974A2 (en) 2006-02-22
MXPA05011243A (es) 2005-12-15
US20070106082A1 (en) 2007-05-10
US20080312312A1 (en) 2008-12-18
US7442812B2 (en) 2008-10-28
CY1110443T1 (el) 2015-04-29
US7585985B2 (en) 2009-09-08
US7842822B2 (en) 2010-11-30
AU2004232798A1 (en) 2004-11-04
DE602004016150D1 (de) 2008-10-09

Similar Documents

Publication Publication Date Title
CY1110443T1 (el) Υποκατεστημενα βενζοπυρανια ως εκλεκτικοι αγωνιστες υποδοχεα-βητα οιστρογονων
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
BRPI0407757A (pt) derivados de benzamida tetracìclica e métodos de uso dos mesmos
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
ECSP088120A (es) Derivados de piridazinona como agonistas del receptorde la hormona tiroidea
BRPI0622054B8 (pt) composto e composição farmacêutica
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
ECSP088298A (es) Modulacion de la expresion del receptor glucocorticoide
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
PE20100252A1 (es) Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
CY1106726T1 (el) Υποκατεστημενα βενζοπυρανια ως επιλεκτικοι συναγωνιστες οιστρογονικου υποδοχεα β
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
DE602004025460D1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
DE60324431D1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
SE0401871D0 (sv) New compositions
AR046672A1 (es) Prevencion y tratamiento de enfermedaes cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,6(10)-trien-3,16alfa-diol

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 495/04, A61P 35/00

Ipc: C07D 495/04 (2011.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.